Diseases [C] » Neoplasms [C04] » Neoplasms by Histologic Type » Leukemia » Leukemia, Myeloid » Leukemia, Myelogenous, Chronic, BCR-ABL Positive » Leukemia, Myeloid, Chronic-Phase
Diseases [C] » Hemic and Lymphatic Diseases [C15] » Hematologic Diseases » Bone Marrow Diseases » Myeloproliferative Disorders » Leukemia, Myelogenous, Chronic, BCR-ABL Positive » Leukemia, Myeloid, Chronic-Phase
Diseases [C] » Pathological Conditions, Signs and Symptoms [C23] » Pathologic Processes » Disease Attributes » Chronic Disease » Leukemia, Myelogenous, Chronic, BCR-ABL Positive » Leukemia, Myeloid, Chronic-Phase
Description
The initial phase of chronic myeloid leukemia consisting of an relatively indolent period lasting from 4 to 7 years. Patients range from asymptomatic to those exhibiting ANEMIA; SPLENOMEGALY; and increased cell turnover. There are 5% or fewer blast cells in the blood and bone marrow in this phase. MeSH
Hierarchy View
Approved Indicated Drugs (3)
Phase 4 Indicated Drugs (3)
Phase 3 Indicated Drugs (14)
Phase 1 Indicated Drugs (58)
Other Experimental Indicated Drugs (6)
Organization Involved with Phase 4 Indications (5)
Organization Involved with Phase 3 Indications (13)
Organization Involved with Phase 2 Indications (67)
Cancer and Leukemia Group B (CALGB)
Case Western Reserve University
City of Hope National Medical Center
Dutch Childhood Oncology Group
ECOG-ACRIN Cancer Research Group
Gruppo Italiano Malattie EMatologiche dell'Adulto
Norwegian University of Science and Technology
Oregon Health and Science University
Organization Involved with Phase 1 Indications (13)
Organization Involved with Other Experimental Indications (1)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.